---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-043590"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2022-11-30T23:59:59+00:00"
generated_at: "2026-06-21T11:35:41.354958+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics guides Q2 cash ~$28-30M; results due Jan 5, 2023

## Summary
- Expected cash at Nov 30, 2022 (Q2 FY2023 end): $28-30 million.
- Net cash increase of ~$3.5-5.5M from Q1 FY2023 end.
- Cash guidance excludes $4.2M CARES Act receivable.
- Q2 FY2023 earnings scheduled for release on or around Jan 5, 2023.

## SEC filing metadata
- accession: 0001140361-22-043590
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2022-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036122043590/0001140361-22-043590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036122043590/brhc10044862_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-043590
- JSON: https://secwatch.observer/filing/0001140361-22-043590.json
- Plain text: https://secwatch.observer/filing/0001140361-22-043590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.